Stocktoria
Contineum Therapeutics, Inc. CTNM
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2024-04-05
Contineum Therapeutics, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | — | $0 | $50.0M |
| R&D expense | $51.5M | $38.4M | $27.6M |
| Operating income | -$68.1M | -$50.9M | $16.1M |
| Income tax | $0 | $0 | $450,000 |
| Net income | -$60.0M | -$42.3M | $22.7M |
| EPS (diluted) | $-2.17 | $-2.18 | $0.08 |
| Operating cash flow | -$55.3M | -$32.8M | $19.3M |
| Free cash flow | -$55.5M | -$33.4M | $18.9M |
| Cash & equivalents | $75.6M | $21.9M | $15.5M |
| Total assets | $276.6M | $212.8M | $130.4M |
| Total liabilities | $15.7M | $14.8M | $5.7M |
| Shareholders' equity | $261.0M | $198.1M | -$67.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | — | -100.0% | — |
| Net income growth | — | -286.0% | — |
| EPS growth | — | -2825.0% | — |
| Free cash flow growth | — | -276.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.